Quote this publication Share Print

BETESIL

-
Opinions on drugs - Posted on May 21 2013

Reason for request

Inclusion

-


Clinical Benefit

Substantial

The actual benefit of BETESIL 2.25 mg medicated plaster in the Marketing Authorisation indication is substantial.


Clinical Added Value

no clinical added value

BETESIL 2.25 mg medicated plaster does not offer any improvement in actual benefit (non-existent IAB V) in the treatment strategy for psoriasis and other inflammatory skin disorders that do not respond to less potent corticosteroids.


Contact Us

Évaluation des médicaments

See also